Real-World Epidemiology of Potassium Derangements Among Chronic Cardiovascular, Metabolic and Renal Conditions: A Population-Based Analysis.
chronic heart failure
chronic kidney disease
heart failure
hyperkalemia
hypertension
potassium
Journal
Clinical epidemiology
ISSN: 1179-1349
Titre abrégé: Clin Epidemiol
Pays: New Zealand
ID NLM: 101531700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
03
2020
accepted:
14
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
The aims of the present analysis are to estimate the prevalence of five key chronic cardiovascular, metabolic and renal conditions at the population level, the prevalence of renin-angiotensin-aldosterone system inhibitor (RAASI) medication use and the magnitude of potassium (K We used data from more than 375,000 individuals, 55 years of age or older, included in the population-based healthcare database of the Catalan Institute of Health between 2015 and 2017. The conditions of interest were chronic heart failure (CHF), chronic kidney disease (CKD), diabetes mellitus, ischemic heart disease and hypertension. RAASI medications included angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists (MRAs) and renin inhibitors. Hyperkalemia was defined as K The high prevalence of K
Sections du résumé
BACKGROUND
BACKGROUND
The aims of the present analysis are to estimate the prevalence of five key chronic cardiovascular, metabolic and renal conditions at the population level, the prevalence of renin-angiotensin-aldosterone system inhibitor (RAASI) medication use and the magnitude of potassium (K
METHODS AND RESULTS
RESULTS
We used data from more than 375,000 individuals, 55 years of age or older, included in the population-based healthcare database of the Catalan Institute of Health between 2015 and 2017. The conditions of interest were chronic heart failure (CHF), chronic kidney disease (CKD), diabetes mellitus, ischemic heart disease and hypertension. RAASI medications included angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists (MRAs) and renin inhibitors. Hyperkalemia was defined as K
CONCLUSION
CONCLUSIONS
The high prevalence of K
Identifiants
pubmed: 32982459
doi: 10.2147/CLEP.S253745
pii: 253745
pmc: PMC7494006
doi:
Types de publication
Journal Article
Langues
eng
Pagination
941-952Informations de copyright
© 2020 Jiménez-Marrero et al.
Déclaration de conflit d'intérêts
Josep Comin-Colet had received speaker fees from Vifor Pharma. The authors report no other potential conflicts of interest for this work.
Références
Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):613-9
pubmed: 22541282
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 1999 Sep 2;341(10):709-17
pubmed: 10471456
J Nephrol. 2018 Oct;31(5):653-664
pubmed: 29882199
Circulation. 2018 Oct 23;138(17):e426-e483
pubmed: 30354655
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
Am J Cardiol. 2012 May 15;109(10):1510-3
pubmed: 22342847
Clin J Am Soc Nephrol. 2012 Aug;7(8):1234-41
pubmed: 22595825
J Am Heart Assoc. 2018 May 22;7(11):
pubmed: 29789332
J Am Coll Cardiol. 2018 Jan 16;71(2):201-230
pubmed: 29277252
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
J Am Heart Assoc. 2017 Jul 19;6(7):
pubmed: 28724651
Circulation. 2018 Mar 27;137(13):1320-1330
pubmed: 29025765
Kidney Int. 2017 Jul;92(1):26-36
pubmed: 28646995
J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93
pubmed: 23810881
J Am Coll Cardiol. 2016 Oct 4;68(14):1575-89
pubmed: 27687200
Eur Heart J. 2018 May 1;39(17):1535-1542
pubmed: 29554312
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):245-252
pubmed: 28143865
Am J Nephrol. 2017;46(3):213-221
pubmed: 28866674
Eur J Heart Fail. 2018 May;20(5):923-930
pubmed: 29327797
Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):180-188
pubmed: 29726985
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
JAMA. 2015 Nov 10;314(18):1973-5
pubmed: 26547470